GlassScriptPhysician profile
Jason Casselman
NPI 1538456462
$2,282.24
in general payments reported to CMS, 2019-2025
17 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $289 · 2021: $124 · 2022: $550 · 2023: $295 · 2024: $401 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.92 |
| Education | $107.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $517.89 | 2020-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $487.68 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $324.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $233.38 | 2019-2025 | |
| Genzyme Corporation | $160.15 | 2022-2025 | |
| Amgen INC. | $143.87 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $115.27 | 2020-2025 | Eohilia, Cuvitru |
| Csl Behring | $89.63 | 2019-2024 | Hizentra |
| Grifols USA, LLC | $41.85 | 2023-2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.74 | 2019-2020 | |
| Kaleo, INC. | $27.74 | 2022-2023 | Auvi-Q |
| Genentech USA, INC. | $22.86 | 2021 | |
| Pfizer INC. | $20.30 | 2022 | |
| Stryker Corporation | $20.14 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $19.27 | 2025 | Neffy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14.45 | 2024 | Voquezna |
| Shire North American Group INC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Casselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.